Clinical Application of Radiolabeled Human X Human Monoclonal Antibody with Interferon in the Treatment of Malignant Glioma—Preliminary Report
Clinical application of human monoclonal antibody (MAb) CLN-IgG was conducted to 7 patients of recurrent malignant glioma. 131-I labeled MAb was administered intratumorouly and scintigraphy was monitored. Specific incorporation of radioMAb was demonstrated on the image, indicating the 10% of radioactivity was distributed in the tumor region. Concomitant administration of interferon enhanced the efficacy of this therapy. The beneficial results have been obtained in 5 patients. No side effects was observed. This radio-immunotherapy holds future promise as a new therapeutic approach to malignant gliomas.
KeywordsMalignant Glioma Human Monoclonal Antibody Recurrent Malignant Glioma Neoplastic Meningitis Human Squamous Cell Carcinoma
Unable to display preview. Download preview PDF.
- 7.Richardson RB, Davies AG, Bourne SP, Staddon GE, Jones DH, Kemshead JT, Coackham HB (1986) ‘Radioimmunolocalisation of human brain tumours: Biodistribution of radiolabelled monoclonal antibody UJ13A’, Eur J Nucl Med 12:313–320.Google Scholar
- 12.Takahashi H, Yamaguchi F, Nakazawa S (1990) ‘An experimental study of monoclonal antibody and cytokine on human malignant glioma’, 3rd Annual Meeting on “Brain and Immune”. 7 July, Nagoya.Google Scholar